Literature DB >> 16722247

The norepinephrine transporter in physiology and disease.

H Bönisch1, M Brüss.   

Abstract

The norepinephrine transporter (NET) terminates noradrenergic signalling by rapid re-uptake of neuronally released norepinephrine (NE) into presynaptic terminals. NET exerts a fine regulated control over NE-mediated behavioural and physiological effects including mood, depression, feeding behaviour, cognition, regulation of blood pressure and heart rate. NET is a target of several drugs which are therapeutically used in the treatment or diagnosis of disorders among which depression, attention-deficit hyperactivity disorder and feeding disturbances are the most common. Individual genetic variations in the gene encoding the human NET (hNET), located at chromosome 16q12.2, may contribute to the pathogenesis of those diseases. An increasing number of studies concerning the identification of single nucleotide polymorphisms in the hNET gene and their potential association with disease as well as the functional investigation of naturally occurring or induced amino acid variations in hNET have contributed to a better understanding of NET function, regulation and genetic contribution to disorders. This review will reflect the current knowledge in the field of NET from its initial discovery until now.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16722247     DOI: 10.1007/3-540-29784-7_20

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  32 in total

1.  Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking.

Authors:  Heinrich J G Matthies; Jessica L Moore; Christine Saunders; Dawn Signor Matthies; Lynne A Lapierre; James R Goldenring; Randy D Blakely; Aurelio Galli
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

2.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

3.  Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis.

Authors:  Sabrina D Robertson; Heinrich J G Matthies; W Anthony Owens; Vidiya Sathananthan; Nicole S Bibus Christianson; J Phillip Kennedy; Craig W Lindsley; Lynette C Daws; Aurelio Galli
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

4.  Temperament and externalizing behavior as mediators of genetic risk on adolescent substance use.

Authors:  Elisa M Trucco; Brian M Hicks; Sandra Villafuerte; Joel T Nigg; Margit Burmeister; Robert A Zucker
Journal:  J Abnorm Psychol       Date:  2016-02-04

5.  Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics.

Authors:  Britta Haenisch; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

Review 6.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

7.  The role of cysteines and histidins of the norepinephrine transporter.

Authors:  Birger Wenge; Heinz Bönisch
Journal:  Neurochem Res       Date:  2013-03-23       Impact factor: 3.996

8.  Interference of the noradrenergic neurotoxin DSP4 with neuronal and nonneuronal monoamine transporters.

Authors:  Birger Wenge; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-10-17       Impact factor: 3.000

9.  N-Ethylmaleimide differentially inhibits substrate uptake by and ligand binding to the noradrenaline transporter.

Authors:  Birger Wenge; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-03-21       Impact factor: 3.000

10.  Subcellular localization of the antidepressant-sensitive norepinephrine transporter.

Authors:  Heinrich J G Matthies; Qiao Han; Angela Shields; Jane Wright; Jessica L Moore; Danny G Winder; Aurelio Galli; Randy D Blakely
Journal:  BMC Neurosci       Date:  2009-06-23       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.